1665 Background: Metabolic patterns on brain F-18 FDG PET can potentially predict the
decline of aMCI to Alzheimers disease dementia (AD) or other dementias. Objectives: To …

Background: Metabolic patterns on brain F-18 fluorodeoxyglucose (FDG) positron emission
tomography (PET) can predict the decline in amnestic mild cognitive impairment (aMCI) to …

Increasingly, clinical trials are being planned in patients with mild cognitive impairment
(MCI) to prevent or delay the onset of dementia in Alzheimer disease (AD) by disease …

Purpose We aimed to identify the cortical regions where hypometabolism can predict the
speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease …

Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission
tomography (PET) and 18 F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard …

This multicenter study examined 18F-FDG PET measures in the differential diagnosis of
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies …

Purpose The aim of this study was to examine the value of fluorodeoxyglucose (FDG)
positron emission tomography (PET) in predicting subsequent rates of functional and …

Decreasing mortality, with consequent progressive aging of the mature adult population, has
led to a rising prevalence of senile dementia. The condition is tremendously costly to …

Background: 18F-FDG-PET is defined as a biomarker of neuronal injury according to the
revised National Institute on Aging–Alzheimer's Association criteria. Objective: The objective …

Biomarkers of Alzheimer disease (AD) can be imaged in vivo and can be used for diagnostic
and prognostic purposes in people with cognitive decline and dementia. Indicators of …